Drug Profile
HM 01 - Helsinn
Alternative Names: HM01Latest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator Helsinn
- Class
- Mechanism of Action Ghrelin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neuropathic pain
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for phase-I development in Neuropathic-pain in Europe (PO)
- 10 Jan 2023 Helsinn has partnered with the unknown organization to develop HM 01 for the treatment of Chemotherapy-induced neuropathic pain (Helsinn pipeline, January 2023)
- 26 Nov 2021 HM 01 is still in phase I trials for Neuropathic-pain (PO) as of November 2021 (Helsinn pipeline; November 2021)